End-to-End Support for Regenerative Medicine Commercialization and Partnering
CM Plus is a hands-on partner supporting every challenge in the regenerative medicine and cell and gene therapy (CGT) fields—from translating academic discoveries into commercial products to facilitating Japan market entry for cutting-edge overseas therapies. Feel free to contact us for a consultation.-
Regulatory consulting support for Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) consultations and regulatory strategy
We provide tailored regulatory strategies across all development phases: non-clinical, clinical, pre-approval, and post-approval. -
GMP and GCTP (Good Gene, Cellular, and Tissue-based Products Manufacturing Practice) inspection readiness and quality assurance (QA) system establishment by seasoned consultants
Comprehensive GCTP and GMP inspection support covering domestic and global regulations across injectables, solid dosage forms, APIs, medical devices, and regenerative medical products.
Table of Contents
CM Plus’s Regenerative Medicine Support
Steps from Development to Manufacturing and Commercialization of Regenerative Medical Products
We support our clients across every phase, from basic research through the post-marketing phase.
Do Any of These Challenges Sound Familiar?
- We want to bring our overseas-developed cell or gene therapy pipeline into Japan, but we don’t know how to navigate Japanese regulatory requirements or PMDA consultations.
- We have promising academic-originated assets (seeds), but lack in-house regulatory affairs specialists and don’t know how to handle grant applications or PMDA consultations.
- We are unsure if our internal team alone can meet the latest GCTP requirements or pass inspections by overseas authorities such as the FDA, due to a shortage of inspection-experienced staff.
- Whether entering from another industry, deciding between building an in-house Cell Processing Center (CPC) or outsourcing to a CDMO, or utilizing rental labs, we don’t know how to plan a GCTP-compliant commercialization roadmap or facility design.
- We need specialized support ranging from commercial-scale equipment selection and URS/specification development to facility gap analysis, PMDA pre-consultations, and on-site GCTP audit/inspection accompaniment.

Consult with CM Plus.
- With a diverse team of specialized consultants, CM Plus supports regenerative medicine projects from regulatory submission strategies and GCTP quality organization building in the R&D phase to CPC facility design in the manufacturing phase.
Furthermore, by integrating our consulting and engineering expertise, we deliver seamless one-stop solutions tailored to your needs.
Case Examples & Solutions
Here are concrete examples of how we support clients based on their specific situations.
① Regenerative Medicine Developers & CDMOs
We want to launch a regenerative medicine business, but don’t know where to start.
While we have manufacturing facilities, we are concerned about whether we can comply with the latest GCTP requirements and pass FDA or other overseas regulatory inspections on our own.
[Solution] Commercialization Roadmap Planning, Gap Analysis, Mock Inspections & On-Site Inspection Support [▼ View Details]
① Regenerative Medicine Developers & CDMOs

We want to launch a regenerative medicine business, but don’t know where to start.
While we have manufacturing facilities, we are concerned about whether we can comply with the latest GCTP requirements and pass FDA or other overseas regulatory inspections on our own.
[Solution] Commercialization Roadmap Planning, Gap Analysis, Mock Inspections & On-Site Inspection Support [▼ View Details]

A key to successfully launching a regenerative medicine business is establishing a well-structured roadmap (master schedule) that covers all required procedures and assessments in the optimal sequence. Because developing such a roadmap demands advanced expertise and hands-on experience, involvement from specialists well-versed in regulatory affairs, QMS, and pharmaceutical/regenerative medicine development is essential. CM Plus’s team includes consultants specializing in regenerative medicine, as well as numerous experts in regulatory submissions and QMS implementation. We organize every step—from basic research, non-clinical and clinical studies, and quality testing to Marketing Approval, Marketing Authorization Holder (MAH) licensing, GCTP compliance, and Foreign Manufacturer Accreditation—to help you plan and build an actionable roadmap.
We also conduct gap analyses based on the latest GCTP requirements and overseas regulatory inspection standards, followed by realistic mock inspections. Our consultants, backed by extensive inspection track records, provide end-to-end support from pre-consultation meetings with regulatory authorities to on-site accompaniment during actual inspections.
② Equipment & Reagent Manufacturers Entering the Regenerative Medicine Market
We want to market our products to the regenerative medicine industry,
but we lack GCTP knowledge and aren’t confident we can pass supplier audits…
[Solution] GCTP Training, Quality Organization Building & Mock Supplier Audits [▼ View Details]
② Equipment & Reagent Manufacturers Entering the Regenerative Medicine Market

We want to market our products to the regenerative medicine industry,
but we lack GCTP knowledge and aren’t confident we can pass supplier audits…
[Solution] GCTP Training, Quality Organization Building & Mock Supplier Audits [▼ View Details]

Compliance with GCTP regulations is mandatory in the regenerative medicine sector. CM Plus provides GCTP training programs and organizational consulting tailored to GCTP standards for equipment and reagent manufacturers serving the regenerative medicine market. We also conduct mock supplier audits modeled on actual audits performed by regenerative medicine developers, complete with GCTP compliance checks and gap analyses. Leveraging multi-disciplinary perspectives covering product characteristics, GCTP, and facility engineering, we deliver our signature one-stop consulting support.
③ Domestic & Overseas Academic Spin-Offs and Regenerative Medicine Startups
We are developing promising early-stage assets or aiming to expand our overseas products into Japan, but we have no in-house regulatory affairs specialists and don’t know how to proceed with PMDA consultations or Japanese regulatory procedures.
[Solution] Comprehensive Development Planning, PMDA Consultation Support & End-to-End Japan Market Entry [▼ View Details]
③ Domestic & Overseas Academic Spin-Offs and Regenerative Medicine Startups

We are developing promising early-stage assets or aiming to expand our overseas products into Japan, but we have no in-house regulatory affairs specialists and don’t know how to proceed with PMDA consultations or Japanese regulatory procedures.
[Solution] Comprehensive Development Planning, PMDA Consultation Support & End-to-End Japan Market Entry [▼ View Details]

Our experienced regulatory consultants provide end-to-end support—from structuring development roadmaps and preparing PMDA consultation packages to assisting with public grant applications. Even for academic spin-offs without dedicated in-house regulatory staff, we help visualize the entire development pathway so you can advance each milestone with confidence.
Furthermore, in collaboration with domestic and international networks such as JETRO, the Forum for Innovative Regenerative Medicine (FIRM), and the Foundation for Biomedical Research and Innovation at Kobe (FBRI), we bridge overseas biotech startups into the Japanese market. From bilingual regulatory and GCTP consultations to specialized interpreter dispatch and English documentation support, we offer complete one-stop support.
One-Stop Services for Regenerative Medicine
Our seasoned regenerative medicine consultants and engineers provide tailored services to meet your specific project needs.
QMS/GCTP Consulting [▼ View Details]

QMS and GCTP organization setup support, GCTP training programs, supplier management support, gap analysis, regulatory inspection readiness support, etc.
Regulatory Affairs Consulting [▼ View Details]

Development plan preparation, PMDA consultation support, licensing and accreditation support (Marketing Authorization Holder (MAH) license, manufacturing license, and Foreign Manufacturer Accreditation, including responses to regulatory inquiries), preparation of marketing approval applications and CTD dossiers, etc.
Facility & Equipment Assessment / Construction Support [▼ View Details]

Conceptual and basic facility design support for CPC construction projects, production equipment selection and URS/specification preparation, Construction Management (CM) for CPC builds, etc.
- CPC: Short for Cell Processing Center
(also referred to internationally as CPF, Cell Processing Facility).
A facility that processes cells for use in cell therapy and regenerative medicine.
Under Japan’s Act on the Safety of Regenerative Medicine (ASRM), a facility manufacturing specified processed cells must submit a notification to, or obtain a license from, the Minister of Health, Labour and Welfare (MHLW), depending on the type of facility, and is assigned a facility number.
Validation Support [▼ View Details]

Preparation of equipment qualification and validation documentation (IQ/OQ/PQ), drafting of Standard Operating Procedures (SOPs), validation management services, etc.
Overseas & Multilingual Business Support [▼ View Details]

Overseas plant construction project support, Foreign Manufacturer Accreditation acquisition support, specialized interpreter dispatch for overseas audits, English technical documentation support, etc.
What Are Regenerative Medical Products? (Classification under Japan’s PMD Act)
Regenerative medical products are products that utilize cells or genes to treat or prevent diseases and injuries. Under Japan’s Pharmaceuticals and Medical Devices Act (PMD Act), regenerative medical products are defined as follows:
- 1.Processed human or animal cells intended for:
(a) Reconstruction, repair, or formation of human or animal body structures or functions
(b) Treatment or prevention of human or animal diseases - 2.Products containing genes introduced into human or animal cells to be expressed in the body
for the treatment of human or animal diseases

Under the PMD Act, regenerative medical products are regulated as a distinct category separate from pharmaceuticals and medical devices. Because they utilize living cells or viral vectors as the product itself, they require specialized manufacturing and quality control systems distinct from conventional drugs or devices.
"Products" vs. "Medical Care" in Regenerative Medicine
In Japan, different legal frameworks apply depending on whether regenerative medicine is supplied commercially as a product by a company or provided as medical treatment within a medical institution. Commercial products are regulated under the Pharmaceuticals and Medical Devices Act (PMD Act), requiring manufacturing facilities and quality/manufacturing control compliant with the GCTP Ministerial Ordinance. Conversely, therapies administered within medical institutions are governed by the Act on the Safety of Regenerative Medicine (ASRM), under which they must be provided as clinical research or self-pay (uninsured) treatment.












